GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

Cell UK by Oxford’s Global, London (UK) & Virtual

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

Mitochondrial Diseases Conference 2021 by Mitocon, Virtual

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual

39th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), San Antonio, TX (USA)

GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics